- Home
- ELAB vs ACON Comparison
ELAB vs ACON Comparison
Compare ELAB & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELAB
- ACON
- Stock Information
- Founded
- ELAB 2020
- ACON 2008
- Country
- ELAB United States
- ACON United States
- Employees
- ELAB N/A
- ACON N/A
- Industry
- ELAB
- ACON Retail: Computer Software & Peripheral Equipment
- Sector
- ELAB
- ACON Technology
- Exchange
- ELAB Nasdaq
- ACON Nasdaq
- Market Cap
- ELAB 6.6M
- ACON 7.1M
- IPO Year
- ELAB 2023
- ACON 2022
- Fundamental
- Price
- ELAB $4.55
- ACON $12.61
- Analyst Decision
- ELAB
- ACON Buy
- Analyst Count
- ELAB 0
- ACON 2
- Target Price
- ELAB N/A
- ACON $481.00
- AVG Volume (30 Days)
- ELAB 418.9K
- ACON 370.3K
- Earning Date
- ELAB 05-14-2025
- ACON 05-14-2025
- Dividend Yield
- ELAB N/A
- ACON N/A
- EPS Growth
- ELAB N/A
- ACON N/A
- EPS
- ELAB N/A
- ACON N/A
- Revenue
- ELAB N/A
- ACON $49,289.00
- Revenue This Year
- ELAB N/A
- ACON N/A
- Revenue Next Year
- ELAB N/A
- ACON $186.36
- P/E Ratio
- ELAB N/A
- ACON N/A
- Revenue Growth
- ELAB N/A
- ACON N/A
- 52 Week Low
- ELAB $3.88
- ACON $9.75
- 52 Week High
- ELAB $1,064.00
- ACON $6,241.05
- Technical
- Relative Strength Index (RSI)
- ELAB 35.23
- ACON 33.96
- Support Level
- ELAB $4.08
- ACON $9.75
- Resistance Level
- ELAB $5.07
- ACON $15.08
- Average True Range (ATR)
- ELAB 0.86
- ACON 3.14
- MACD
- ELAB 0.26
- ACON 12.50
- Stochastic Oscillator
- ELAB 14.62
- ACON 13.43
About ELAB Elevai Labs Inc.
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
About ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The Company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.